Anavex Life Sciences, OR Anavex, a leading biopharmaceutical company, has reported positive findings from the
48-week, open-label extension of their phase 2 study of blarcamesine in
patients with Parkinson’s disease dementia (PDD). The investigational agent,
also known as ANAVEX2-73, demonstrated favorable safety and efficacy outcomes,
meeting its primary and secondary objectives in this cohort of individuals with PDD. 

Despite a delay in the start of the extension phase due to the COVID-19 pandemic, patients who
chose to continue treatment with blarcamesine experienced significant
improvements in their PDD symptoms throughout the 48-week period. The results
showed consistent longitudinal improvement in clinical symptoms under active
treatment with ANAVEX2-73. 

Christopher U. Missling, PhD, President and CEO of Anavex, expressed his optimism about the study’s
findings, stating, “It is encouraging that the patients’ clinical symptoms
consistently improved longitudinally over time during the extension phase under
active ANAVEX2-73 treatment.” 

The study measured various efficacy endpoints, including the Movement Disorder Society-Unified
Parkinson’s Disease Rating Scale (MDS-UPDRS) Parts II and III, as well as the
Clinical Global Impression-Improvement (CGI-I) scale. Patients who resumed
treatment with blarcamesine consistently demonstrated improvements in these
measures, indicating the potential of ANAVEX2-73 to slow and even reverse the
life-altering symptoms of Parkinson’s disease, which is a pressing unmet need worldwide. 

In addition to the primary and secondary endpoints, the study also assessed cognitive function and
sleep behavior in patients. The Montreal Cognitive Assessment scores showed
mean improvements, and the REM Sleep Behavior Disorder Screening Questionnaire indicated
positive changes as well. These findings highlight the potential of
blarcamesine to address multiple aspects of Parkinson’s disease, including
cognitive impairment and sleep disturbances. 

While the study sample size was small, and caution must be exercised in interpreting the
results, the positive outcomes observed in this phase 2 extension study are
promising. The encouraging data from this trial sets the stage for further
investigations of ANAVEX2-73 in larger, more comprehensive studies to establish
its efficacy and safety profile. 

Anavex Life Sciences is committed to advancing innovative therapies for neurological disorders, and the
positive results from this study provide hope for patients with Parkinson’s
disease dementia. The company plans to conduct a 6-month study in Parkinson’s
disease to further evaluate the potential of blarcamesine. 

As research in the field of neurology progresses, the development of effective treatments for
neurodegenerative diseases such as Parkinson’s disease remains a top priority.
The promising results from Anavex’s phase 2 extension study bring us one step
closer to achieving this goal and bringing much-needed relief to patients
suffering from Parkinson’s disease dementia. Follow this page on Twitter, to learn more. 

  

More about Anavex on https://www.bloomberg.com/profile/company/AVXL:US